|
|
Home > Healthcare > Pharmaceutical > General Pharmaceutical
Pipeline Insight: Colorectal Cancer - Growing trend towards personalized medicine
|
| Published Date:
October 2009
Published By:
Datamonitor
Page Count:
51
Order Code:
R313-56386
|
|
|
|
Introduction
CRC incidence will be over 490,000 cases by 2018 in the seven major markets. This large patient base will translate into a high commercial potential for the development of novel, more effective therapies. Currently, there are 77 agents in development for CRC, 4 of which are in late-phase development. Collectively, they are forecast to achieve sales of $1,398m by 2018.
Scope- Examination of the CRC pipeline with in-depth clinical and commercial profiles of Phase III candidates
- Seven major pharmaceutical market sales forecasts for Phase III pipeline products through to 2018
- Segmentation and analysis of the current CRC pipeline by developmental phase, drug class and company
- Insight and analysis of market potential including commercial opportunity, epidemiology and discussion of unmet needs
Highlights
The CRC pipeline consists of 77 drugs, of which 60% are molecular targeted therapies (MTTs), 22% are immunotherapies, and 17% are cytotoxic therapies. MTTs constitute the bulk of the CRC pipeline. This is in line with R&D in other tumor types, where there is a shift away from standard cytotoxic therapies towards MTTs and personalized medicine.
The late-phase CRC pipeline consists only of MTTs. Except for one agent; all the others are being investigated in previously-treated patients. Drug developers appear to be pursuing approval for treatment in the second-line setting where barriers to market entry are lower and the high level of unmet need may facilitate a drug's uptake and approval.
Aflibercept (VEGF-Trap; Regeneron/Sanofi-Aventis) is forecast to achieve the highest level of sales among the late-phase pipeline candidates in the CRC market, generating £604m by 2018 in the seven major pharmaceutical markets.
Reasons to Purchase- Identify key drugs and companies within the CRC pipeline based on sales forecasts to 2018 and Datamonitor drug assessment.
- Characterize unmet need and poorly served patient subsets within the CRC market and assess the potential for pipeline products to fulfil them.
- Segmentation and analysis of the current CRC pipeline by developmental phase, drug class, company and indication.
Please note: this is delivered as a Zip file.
|
Similar Products
• United States Type 2 Diabetes Market
Published Nov 2009 by Intellent
• Company Financials: Bayer AG
Published Nov 2009 by Datamonitor
• Thailand Pharmaceuticals and Healthcare Report Q1 2010
Published Nov 2009 by Business Monitor International
• Argentina Pharmaceuticals and Healthcare Report Q1 2010
Published Nov 2009 by Business Monitor International
• Takeda Pipeline, Products, Performance, Potential
Published Nov 2009 by Espicom Healthcare Intelligence
• Poland Pharmaceuticals and Healthcare Report Q1 2010
Published Nov 2009 by Business Monitor International
• Merck & Co. Performance, Products, Pipeline and Potential
Published Nov 2009 by Espicom Healthcare Intelligence
• Australia Pharmaceuticals and Healthcare Report Q1 2010
Published Nov 2009 by Business Monitor International
• Nigeria Pharmaceuticals and Healthcare Report Q1 2010
Published Nov 2009 by Business Monitor International
• Kenya Pharmaceuticals and Healthcare Report Q1 2010
Published Nov 2009 by Business Monitor International
|
|
|
|
0 items
